Explore
Settings

Settings

×

Reading Mode

Adjust the reading mode to suit your reading needs.

Font Size

Fix the font size to suit your reading preferences

Language

Select the language of your choice. NewsX reports are available in 11 global languages.
we-woman
Advertisement

Supreme Court Halts New Rules On Misleading Ayurvedic Advertisements

The Supreme Court has halted the Centre's move to remove Rule 170 of the Drugs and Cosmetics Rules, 1945, which prevented misleading ads for Ayurvedic, Siddha, and Unani drugs.

Supreme Court Halts New Rules On Misleading Ayurvedic Advertisements

On Tuesday, the Supreme Court paused the Centre’s notification that had omitted Rule 170 of the Drugs and Cosmetics Rules, 1945, which pertains to the prohibition of misleading advertisements for Ayurvedic, Siddha, and Unani drugs. The bench, comprising Justices Hima Kohli and Sandeep Mehta, stated that Rule 170 of the 1945 Rules shall remain in effect until further orders are issued.

Background on Rule 170

Rule 170 of the Drugs and Cosmetics Rules was designed to prevent misleading advertisements concerning Ayurvedic, Siddha, and Unani drugs. However, the Ministry of Ayush, through a notification dated July 1, 2024, omitted Rule 170 from the 1945 regulations.

Court’s Ruling on the Notification

The Supreme Court criticized the notification of omission, stating that it contradicts a previous court order. Instead of withdrawing the notification issued on August 29, 2023, which recommended omitting Rule 170, the Ministry of Ayush released a new notification on July 1, 2024.

MUST READ: Kolkata Protests: BJP Demands Polygraph Test for Mamata Banerjee Amid Controversy Over Kolkata Doctor’s Death

Ministry’s Response and Court’s Decision

The lawyer representing the Ministry of Ayush requested additional time to clarify the reasons behind the omission. The court granted this request but maintained that until clarification is provided, the notification from July 1, 2024, removing Rule 170 will remain stayed, meaning Rule 170 continues to be enforced.

Legal Context and Future Proceedings

The Supreme Court had previously asked the Union of India to explain the letter dated August 29, 2023, issued by the Under Secretary of the Ministry of Ayush. This letter informed state and union territory licensing authorities and drug controllers of the Ayurvedic Siddha and Unani Drugs Technical Advisory Board’s (ASUDTAB) recommendation to proceed with the final notification omitting Rule 170.

The court is addressing concerns related to misleading health claims made by advertisements. The issue came to light in connection with a petition filed by the Indian Medical Associations against Patanjali for making misleading claims in its advertisements.

(WITH INPUTS FROM ANI)

ALSO READ: What Did RG Kar Medical College Principal Reveal In Lie Detector Test ?

mail logo

Subscribe to receive the day's headlines from NewsX straight in your inbox